Government,
Criminal
Nov. 10, 2020
Questions over Pfizer clinical trial tool’s patent status under safe harbor rules
Some legal experts say the stakes are now exponentially higher due to the greater potential compensation plaintiff Allele Biotechnology is seeking in a patent infringement lawsuit it filed against Pfizer and its collaborator, BioNTech, in San Diego last month.
With Pfizer Inc. on the cusp of getting its COVID-19 vaccine federally approved, questions remain as to whether the company used a patented research tool during its clinical trials that is not exempt from infringement under safe harbor provisions.
Some legal experts say the stakes are now exponentially higher due to the greater potential compensation plaintiff Allele Biotechnology is seeking in a patent infringement lawsuit it fi...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In